Tvardi Therapeutics, Inc. (TVRD)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.25+$0.1900 (+17.92%) on the dayAs of the close; data may be delayed.
TVRD price, last 12 months
Key stats
- Previous close
- $1.06
- Open
- $1.10
- Day range
- $1.07 – $1.28
- 52-week range
- $0.9300 – $43.65
- Volume
- 653.1K
- Avg volume (20 days)
- 200.6K
- Market cap
- $17.6M
Performance
1W−23.3%
1M−29.8%
3M−16.7%
6M−62.5%
YTD−70.9%
1Y−96.6%
vs S&P 500, 1Y−113.4 pts
Technicals and fundamentals
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $17.6M